Quantcast

Latest Intraocular pressure Stories

2010-04-05 07:00:00

SOUTH SAN FRANCISCO, Calif., April 5 /PRNewswire/ -- Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital. New investors Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital also joined the round. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei...

2010-03-24 08:42:00

GENEVA, March 24 /PRNewswire-FirstCall/ -- STMicroelectronics (NYSE: STM), the world's leading supplier(1) of MEMS (Micro-Electro-Mechanical Systems)(2) devices for consumer and portable applications, has announced that it will develop and supply a wireless MEMS sensor that acts as a transducer, antenna and mechanical support for additional read-out electronics in a breakthrough platform developed by Swiss company Sensimed AG. This solution will enable better management of glaucoma...

2010-03-09 09:30:00

LAWRENCEVILLE, N.J., March 9 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will...

2010-03-08 17:00:00

Early treatment of ocular hypertension appears to reduce the risk of developing glaucoma, especially in individuals at the highest risk, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals. However, this strategy may not offer an absolute benefit in individuals at low risk. Glaucoma is one of the most common causes of blindness in the United States and worldwide, according to background information in the article. High pressure within the...

2010-03-04 10:28:00

LAWRENCEVILLE, N.J., March 4 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that in an independent survey of U.S. ophthalmologists by Frost & Sullivan, Timoptic® was rated the leading brand name of beta blockers for glaucoma. Timoptic received Frost & Sullivan's 2010 Best Practices Award as the "Best Brand Name of Beta Blockers for Glaucoma," based on its Brand Perception Index (BPI) score, reflecting strong...

2009-10-26 23:14:07

Oct. 26 scientific program highlights A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American...

2009-08-19 09:00:00

LAWRENCEVILLE, N.J., Aug. 19 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic...

2009-07-13 15:56:26

The overall number of glaucoma surgical procedures appears to be increasing, but payments by Medicare for the procedures have been decreasing, according to a report in the July issue of Archives of Ophthalmology, one of the JAMA/Archives journals.Glaucoma is one of the leading causes of blindness worldwide and currently affects more than 2 million people in the United States, according to background information in the article. "Management and treatment of glaucoma can be costly, and it has...

2009-07-07 09:10:00

NEW YORK, MONTREAL and SAN DIEGO, CA, July 7 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc. of San Diego California, announced that Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. These unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets. High Interest in a New Approach to Glaucoma Treatment One...

2009-07-01 08:34:20

The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions. One study reports on silent cerebral infarcts (SCI) incidence and visual field loss in patients with normal-tension glaucoma; the other correlates inflammation biomarkers with corneal transplant rejection in herpes simplex patients.Silent Cerebral Infarcts: Risk Factor for Visual Field Loss as Well as for Stroke?Health...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'